Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patient with parkinson's disease

Movement Disorders

Volumn 20, Issue 6, 2005, Pages 734-739

  Contin, Manuela ^a   Martinelli, Paolo ^a   Mochi, Mirella ^a   Riva, Roberto ^a   Albani, Fiorenzo ^a   Baruzzi, Agostino ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

COMT polymorphism; Levodopa; Parkinson's disease; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMANTADINE; BENSERAZIDE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ANTIPARKINSON AGENT; BENSERAZIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG RESPONSE; DYSKINESIA; FEMALE; GENE ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG INTERACTION; GENETICS; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; PHARMACOGENETICS; REACTION TIME;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; AREA UNDER CURVE; BENSERAZIDE; CATECHOL O-METHYLTRANSFERASE; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; REACTION TIME;

EID: 22844450383     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20410     Document Type: Article

References (21)

1. Zhu BT. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: Importance in pathophysiology and pathogenesis. Curr Drug Metab 2002;3:321-349.
2. Mannisto PT, Ulmanen I, Lundstrom K, et al. Characteristics of catechol-O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992;39:291-350.
3. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum R. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-250.
4. McLeod HL, Syvanen AC, Githang'a J. et al. Ethnic differences in catechol-O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics 1998;8: 195-199.
5. Boudikova B, Szumlanski C, Maidak B, Weinshilboum R. Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 1990;48:381-389.
6. Syvanen AC, Tilgmann C, Rinne J, Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and Parkinsonian patients in Finland. Pharmacogenetics 1997;7:65-71.
7. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
8. Robertson DRC, Wood ND, Everest H, et al. The effect of age on the pharmacokinetics of levodopa administered alone and in presence of carbidopa. Br J Clin Pharmacol 1989;28:61-69.
9. Reilly DK, Rivera-Calimlim L, Van Dyke D. Catechol-O-methyltransferase activity: A determinant of levodopa response. Clin Pharmacol Ther 1980;28:278-285.
10. Rivera-Calimlim L, Deepak T, Anderson R, Joint R. The clinical picture and plasma levodopa metabolite profile of Parkinsonian non-responders. Arch Neurol 1977;34:228-232.
11. Woitalla D, Karwasz R, Muller Th, Przuntek H, Kuhn W. The activity of catechol-O-methyltransferase in parkinsonian patients with "on-off fluctuations." J Neural Transm 2000;107:105-111.
12. Lee MS, Lyoo CH, Ulmanen I, Syvanen AC, Rinne JO. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci Lett 2001;298: 131-134.
13. Watanabe M, Harada S, Nakamura T. et al. Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology 2003:48:190-193.
14. Gibb WRG, Lees AJ. The relevance of the Lewy body to pathogenesis of idiopathic Parkinson's disease J Neurol Neurosurg Psychiatry 1988;51:745-752.
15. Contin M, Riva R, Martinelli P, Albani F, Avoni P, Barozzi A. Levodopa therapy monitoring in patients with Parkinson's disease: a kinetic-dynamic approach. Ther Drug Monit 2001;23:621-629.
16. Baruzzi A, Contin M. Riva R, Albani F. Simple and rapid micromethod for the determination of levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr B Biomed Appl 1986;375:165-169.
17. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394.
18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
19. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000:59:1233-1250.
20. Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RM, Brant R, Campbell RC. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol 2000;23: 143-148.
21. Lee MS, Kim HS, Cho EK, Lim JH, Rinne JO. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 2002;58:564-567.